Santa Clara, CA, July 24, 2013 — ProteinSimple today introduced the FluorChem R system as the next member of the FluorChem product family. The FluorChem R system is a fully integrated, multimode gel and Western blot imager with chemiluminescent, fluorescent, and infrared detection capabilities.
The FluorChem R system takes Western blot imaging to the next level by combining three key elements — application flexibility, sensitivity and ease-of-use. Its 8.3 megapixel CCD camera and simple 10.4 inch touch screen interface allow researchers to detect even the faintest band — and get crisp, clear images every time. Like the preceding FluorChem products, it is equipped with an on-board computer and intuitive browser-based Digital Darkroom acquisition and analysis software, so the FluorChem R system is ready to use right out the box.
"The FluorChem R system brings together three detection modes in a single instrument, making it the 'do all' instrument in the gel and blot imaging space today," commented John Proctor, Director of Marketing at ProteinSimple. "The multimode capability of the FluorChem R system will enable researchers to use a broad array of secondary antibodies and dyes without additional instruments or reagents; ultimately maximizing laboratory bench space."
Read more: http://www.proteinsimple.com/news_details.html?id=47&page=news.html
ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes
San Diego, California, July 10, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that it completed a private equity financing transaction, providing the Company $10.6 million through the sale of Series C-1 Preferred Stock, together with warrants to purchase stock. The financing, conducted as a rights offering to ViaCyte Series B and C Preferred Stock holders, included the Company’s largest existing investors – Johnson & Johnson Development Corporation, Sanderling Ventures and Asset Management Company (Johnson Trust).
Judy Twist shares with Lisa her success with the program Prevent.